TRANSFORMING THE PARADIGM OF CARE FOR CLASSIC HODGKIN LYMPHOMA

• KARA M. KELLY· PROFESSOR
• SARAH RUTHERFORD· PROFESSOR
• BASTIAN VON TRESCKOW· PROFESSOR

• KARA M. KELLY· RELATORE
• SARAH RUTHERFORD· RELATORE
• BASTIAN VON TRESCKOW· RELATORE

Ragione sociale

MEET AND WORK SRL

Stato accreditamento

STANDARD - 1° rinnovo

Di processo

The congress will explore cutting-edge therapies and emerging molecular targets in the treatment of relapsed or refractory multiple myeloma. Experts will discuss innovative strategies and novel drug developments aimed at improving patient outcomes. This event will highlight the future myeloma treatment and ongoing research efforts.

Professionali

The congress will explore cutting-edge therapies and emerging molecular targets in the treatment of relapsed or refractory multiple myeloma. Experts will discuss innovative strategies and novel drug developments aimed at improving patient outcomes. This event will highlight the future myeloma treatment and ongoing research efforts.

Di sistema

The congress will explore cutting-edge therapies and emerging molecular targets in the treatment of relapsed or refractory multiple myeloma. Experts will discuss innovative strategies and novel drug developments aimed at improving patient outcomes. This event will highlight the future myeloma treatment and ongoing research efforts.

#3Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura

Area: Obiettivi formativi tecnico-professionali

Partecipanti max

500

Verifica presenza

Firma Di Presenza

Verifica apprendimento

Questionario A Risposta Multipla